Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Hai-Tao Guan
Antitumor Activity of the Selective Cyclooxygenase-2 Inhibitor, Celecoxib, on Breast Cancer in Vitro and in Vivo
Cancer Cell International
Cancer Research
Oncology
Genetics
Distinct Role of the Fas Rs1800682 and FasL Rs763110 Polymorphisms in Determining the Risk of Breast Cancer Among Han Chinese Women
Drug Design, Development and Therapy
Drug Discovery
Pharmacology
Pharmaceutical Science
Related publications
The Selective Cyclooxygenase-2 Inhibitor Celecoxib Reduces Bone Resorption, but Not Bone Formation, in Ovariectomized Mice in Vivo
Tohoku Journal of Experimental Medicine
Biochemistry
Medicine
Genetics
Molecular Biology
Antiangiogenic Activity of the Selective Cyclooxygenase 2 Inhibitor Rofecoxib in Human Colorectal Cancer Liver Metastases
Gut
Gastroenterology
The Protective Effects of Ursodeoxycholic Acid and the Selective Cyclooxygenase-2 Inhibitor Celecoxib on Liver Damage in an Experimental Cholestasis Model
Experimental Biomedical Research
Antitumor Agents. 272. Structure−Activity Relationships and in Vivo Selective Anti-Breast Cancer Activity of Novel Neo-Tanshinlactone Analogues
Journal of Medicinal Chemistry
Drug Discovery
Molecular Medicine
Antitumor Activities of JTP-74057 (GSK1120212), a Novel MEK1/2 Inhibitor, on Colorectal Cancer Cell Lines in Vitro and in Vivo
International Journal of Oncology
Cancer Research
Oncology
Cyclooxygenase-2 Inhibitor Celecoxib Attenuates Joint Contracture Following Immobilization in Rat Knees
BMC Musculoskeletal Disorders
Rheumatology
Orthopedics
Sports Medicine
A Tumor-Selective Somatostatin Analog (TT-232) With Strong in Vitro and in Vivo Antitumor Activity.
Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
Changes in Antitumor Response in C57bl/6j-Min/+ Mice During Long-Term Administration of a Selective Cyclooxygenase-2 Inhibitor
Cancer Research
Cancer Research
Oncology
Antitumor Activity of the Selective Pan-Raf Inhibitor TAK-632 in BRAF Inhibitor-Resistant Melanoma
Cancer Research
Cancer Research
Oncology
